Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease.
|
| Abstract |
The complement system is an evolutionarily ancient arm of the innate immune system. It remains, however, one of the last major pathways in immunology for which specific pharmaceutical antagonists have been developed. In recent years, a fundamental role for complement has been described in many different renal diseases, including both pauci-immune as well as immune-complex diseases. Since the 2011 FDA approval of eculizumab, the only marketed complement antagonist, no new therapeutics have entered clinical practice. There are now multiple new agents in clinical trials, from oral molecules to small inhibitory RNA, that target the classical, lectin, and alternative pathways. Herein we summarize several potential renal diseases in which complement inhibitors may provide a therapeutic benefit, as well as specific complement inhibitors in development.
|
|---|---|
| Authors | Catherine Kelleher, Hetal Kocinsky |
| Journal | Advances in chronic kidney disease (Adv Chronic Kidney Dis) Vol. 27 Issue 2 Pg. 95-103 (03 2020) ISSN: 1548-5609 [Electronic] United States |
| PMID | 32553251 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!